Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: Patients with low nicotinamide N-methyltransferase expression benefit significantly from bevacizumab treatment in ovarian cancer

Fig. 6

The association of NNMT expression with bevacizumab response in ovarian cancer patients. a Bevacizumab conferred significant improvements in OS for patients with low NNMT expression (HR: 0.56, 95%CI: 0.31–0.99, Log-rank P = 0.049). b Patients with high NNMT expression didn’t benefit from bevacizumab treatment significantly (HR: 0.85, 95%CI: 0.48–1.49, Log-rank P = 0.561)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us